RenovoRx (RNXT) Non Operating Income (2020 - 2026)
RenovoRx (RNXT) posted Non Operating Income of -$52000.0 for Q1 2026, down 105.25% sequentially from $990000.0 in Q4 2025, and down 107.54% YoY from $690000.0 in Q1 2025.
RenovoRx (RNXT) Non Operating Income (2020 - 2026) Analysis & Trends
RenovoRx has reported Non Operating Income for 7 years, with the latest figure at -$52000.0 in Q1 2026.
- Quarterly Non Operating Income fell 107.54% year-over-year to -$52000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $834000.0 (up 249.19% YoY) and the FY2025 annual result came in at $1.3 million, up 249.48% from the prior year.
- Non Operating Income retreated to -$52000.0 in Q1 2026 per RNXT's latest filing, from $990000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $1.0 million in Q2 2023 and troughed at -$2.0 million in Q4 2024.
- A 5-year average of $87176.5 and a median of $25000.0 in 2022 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income jumped 5140.0% in 2023, then plunged 18445.45% in 2024.
- Over 5 years, Non Operating Income stood at $18000.0 in 2022, then slumped by 38.89% to $11000.0 in 2023, then slumped by 18445.45% to -$2.0 million in 2024, then surged by 149.06% to $990000.0 in 2025, then sank by 105.25% to -$52000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$52000.0, $990000.0, and $113000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 | 438,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 438,000.00 |
| Mar 31, 2026 | -52,000.00 |
| Dec 31, 2025 | 990,000.00 |
| Sep 30, 2025 | 113,000.00 |
| Jun 30, 2025 | -217,000.00 |
| Mar 31, 2025 | 690,000.00 |
| Dec 31, 2024 | -2.02 Mn |
| Sep 30, 2024 | 124,000.00 |
| Jun 30, 2024 | 645,000.00 |
| Mar 31, 2024 | 37,000.00 |
| Dec 31, 2023 | 11,000.00 |
| Sep 30, 2023 | 43,000.00 |
| Jun 30, 2023 | 1.05 Mn |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | 18,000.00 |
| Sep 30, 2022 | 25,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Sep 30, 2021 | -116,000.00 |